Investment management firm RA Capital Management, L.P., operating through its affiliated funds and key principals, has executed a series of purchases involving Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) common stock. The aggregate value of these transactions reached approximately $7.65 million. The acquisition activity was conducted over a concentrated three-day window from June 9 to June 11, 2026.
On the first day of the reporting period, June 9, 2026, the RA Capital Healthcare Fund, L.P. acquired 479,039 shares. These shares were purchased at a weighted average price of $6.91 per share, with the individual transaction prices spanning a range from $6.77 to $7.00. The following day, June 10, 2026, a minimal additional acquisition of 103 shares took place at a fixed price of $7.00 per share. On June 11, 2026, the fund executed a larger block purchase of 548,580 shares. These final shares were acquired at a weighted average price of $7.91 per share, with individual prices varying between $7.605 and $8.00.
These recent purchases have increased the RA Capital Healthcare Fund, L.P.'s indirect holdings in Artiva Biotherapeutics to a total of 16,231,717 shares. The timing of this accumulation aligns with a period of substantial price appreciation for Artiva stock. Over the preceding year, the shares have surged by 308%, and they have climbed 155% over the last six months. At the time of reporting, the stock was trading at $7.97, corresponding to a market capitalization of $360.52 million.
Beyond the primary healthcare fund, other entities within the RA Capital network maintain indirect interests in the company. The RA Capital Nexus Fund, L.P. holds 264,571 shares, while the RA Capital Nexus Fund III, L.P. holds 826,832 shares. Additionally, a separately managed account associated with the group holds 68,320 shares. The reporting owners identified in the filings include RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund, L.P., RA Capital Nexus Fund III, L.P., RA Capital Management, L.P., Peter Kolchinsky, and Rajeev Shah.
RA Capital Management, L.P. is formally identified as a director and a ten percent owner of Artiva Biotherapeutics. Peter Kolchinsky and Rajeev Shah serve as managing members of RA Capital Management GP, LLC, which acts as the general partner for RA Capital Management, L.P. Laura Stoppel, a Principal of RA Capital Management, L.P., also sits on Artiva’s board of directors. The reporting persons have disclaimed beneficial ownership of the reported securities to the extent of their pecuniary interest only.
In parallel with the insider activity, Artiva Biotherapeutics has announced significant regulatory and clinical developments. The company received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration for its AlloNK therapy. This designation applies to the use of AlloNK in combination with rituximab for the treatment of refractory rheumatoid arthritis. The designation facilitates expedited development and review processes, granting the company early and frequent interactions with regulatory officials.
Clinical data presented at the European Alliance of Associations for Rheumatology Congress further supports the company's pipeline. Artiva reported promising results indicating that 71% of rheumatoid arthritis patients achieved an ACR50 response after six months of follow-up. Institutional analyst sentiment also reflects optimism; Cantor Fitzgerald has reiterated its Overweight rating for Artiva Biotherapeutics, maintaining a price target of $40.00. The firm recently hosted a webinar with Artiva’s CEO to discuss strategic progress.
Operational changes at Artiva include the appointment of Diego Miralles, M.D. as President and Head of Research and Development. Miralles stepped down from the board of directors, reducing the board size from eight to seven members. Financial metrics indicate a strong current ratio of 8.16, and the company holds more cash than debt on its balance sheet. However, the company continues to burn through cash. Valuation analysis suggests the stock may be overvalued relative to fair value estimates, despite analyst price targets ranging from $23 to $41.